BioMarin Pharmaceutical I... (BM8.DE)
63.52
0.58 (0.92%)
At close: Dec 11, 2024, 2:43 PM
undefined% (undefined)
| Bid | n/a |
| Market Cap | 12.06B |
| Revenue (ttm) | - |
| Net Income (ttm) | - |
| EPS (ttm) | 0.7 |
| PE Ratio (ttm) | 90.74 |
| Forward PE | n/a |
| Analyst | n/a |
| Ask | n/a |
| Volume | 0 |
| Avg. Volume (20D) | 14.1 |
| Open | 63.02 |
| Previous Close | 62.94 |
| Day's Range | 63.02 - 63.52 |
| 52-Week Range | 58.04 - 90.70 |
| Beta | undefined |
About BM8.DE
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-acetylgalactosamine 4-sulfatase for patients with MPS VI; and Kuvan, a proprietary synthetic oral form o...
Industry Biotechnology
Sector Healthcare
IPO Date Nov 10, 2022
Employees 3,401
Stock Exchange XETRA
Ticker Symbol BM8.DE
Website https://www.biomarin.com